Merck’s Winrevair: Pulmonary arterial hypertension drug shows success ahead of schedule
Strong positive interim data from an earlier Phase 3 trial has led to early cessation of Merck’s pulmonary arterial hypertension...
Verona’s Ohtuvayre shows promise in the treatment and management of Chronic Obstructive Pulmonary Disease
Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term benefits by reducing...
Johnson & Johnson’s Tremfya seeks to expand FDA approval for pediatric indications to treat juvenile psoriatic arthritis
Adult clinical trials found that Tremfya could treat plaque psoriasis by 16 weeks. Follow-up analysis found that roughly 23% of...
Iterum’s Sulopenem receives FDA approval for treatment of uncomplicated urinary tract infections
Sulopenem was superior to amoxicillin/clavulanate and ciprofloxacin in treating antimicrobial resistant uncomplicated urinary tract infections. The antibiotic was safe and...
Sanofi’s Sarclisa approved as first-line for transplant-ineligible multiple myeloma patients
Sarclisa in combination with the VRd regiment was superior to VRd alone in improving survival in stem cell transplant ineligible...
Bayer’s Kerendia demonstrates success in phase 3 clinical trials for treatment of heart failure
A phase 3 trial showed Kerendia reduced the risk of cardiovascular death by 16% compared to placebo. Hyperkalemia was greater...
Tarsus Pharmaceuticals’ Xdemvy demonstrates positive efficacy and safety in treatment for patients with Demodex blepharitis.
Xdemvy is the first and only approved FDA treatment for Demodex blepharitis Xdemvy can achieve collarette reduction of no more...
GSK’s Jemperli in combination with chemotherapy shows improved overall survival in patients with endometrial cancer.
Jemperli in combination with chemotherapy showed a 31% reduction in the risk of death and a 16.4-month improvement in median...
AstraZeneca’s Tagrisso and chemotherapy pairing have been approved in Canada for treatment in locally advanced or metastatic non-small cell lung cancer.
Tagrisso is the first-line therapy for patients whose lung cancer tumors have EGFR exon 19 deletions or exon 21 substitution...
Johnson & Johnson and Legend Biotech’s Carvykti shows improved survival in treatment-experienced multiple myeloma patients
As a 2nd line therapy for multiple myeloma, Carvykti can lower the risk of disease progression or death by 59%...